Intestinal Perforation after Bevacizumab Treatment in Metastatic Colon Cancer: A Rare Case

Durmuş Çetin; Ebubekir Gündeş; Ulaş Aday; Hüseyin Çiyiltepe; Kamuran Değer; Mustafa Duman

doi:10.5798/diclemedj.0921.2016.01.0661

Intestinal Perforation after Bevacizumab Treatment in Metastatic Colon Cancer: A Rare Case

Abstract

Bevacizumab is a monoclonal antibody which is targeting to vascular endothelial growth factor. It has been shown to be a promising drug on metastatic colorectal cancer and is combined with chemotherapeutic agents. One should be aware of serious complications even though bevacizumab is a well-tolerated drug. There are a few intestinal perforation cases that have been reported in the oncologic surgery literature related to the bevacizumab treatment. In this case report, we aimed to represent a 45 years old man who was diagnosed with intestinal perforation after bevacizumab treatment ten months after a metastatic colon cancer surgery.
Key words: Bevacizumab, intestinal perforation, metastatic colorectal cancer

Keywords

Bevacizumab, ince barsak perforasyonu, metastatik kolorektal kanser

References

Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006;28:1779- 1802.
Bernold DM, Sinicrope FA. Advances in chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol 2006;4:808-821.
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
Chen HX, Mooney M, Boron M, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 2006; 24:3354-3360.
Jain RK. Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-989.
Shord SS, Bressler LR, Tierney LA, et al. Understanding and managing the possible adverse effects associated with bevacizumab.
Am J Health Syst Pharm 2009; 66:999-1013.
Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 2007;14:1860-869.

Details

Primary Language

Turkish

Subjects

-

Journal Section

-

Authors

Durmuş Çetin This is me

Ebubekir Gündeş This is me

Ulaş Aday This is me

Hüseyin Çiyiltepe This is me

Kamuran Değer This is me

Mustafa Duman This is me

Publication Date

March 1, 2016

Submission Date

March 29, 2016

Acceptance Date

-

Published in Issue

Year 2016 Volume: 43 Number: 1

DOI

https://doi.org/10.5798/diclemedj.0921.2016.01.0661

IZ

https://izlik.org/JA66FU62GL

Cite

RIS / Bibtex

APA

Çetin, D., Gündeş, E., Aday, U., Çiyiltepe, H., Değer, K., & Duman, M. (2016). Intestinal Perforation after Bevacizumab Treatment in Metastatic Colon Cancer: A Rare Case. Dicle Medical Journal, 43(1). https://doi.org/10.5798/diclemedj.0921.2016.01.0661

AMA

1.Çetin D, Gündeş E, Aday U, Çiyiltepe H, Değer K, Duman M. Intestinal Perforation after Bevacizumab Treatment in Metastatic Colon Cancer: A Rare Case. Dicle Medical Journal. 2016;43(1). doi:10.5798/diclemedj.0921.2016.01.0661

Chicago

Çetin, Durmuş, Ebubekir Gündeş, Ulaş Aday, Hüseyin Çiyiltepe, Kamuran Değer, and Mustafa Duman. 2016. “Intestinal Perforation After Bevacizumab Treatment in Metastatic Colon Cancer: A Rare Case”. Dicle Medical Journal 43 (1). https://doi.org/10.5798/diclemedj.0921.2016.01.0661.

EndNote

Çetin D, Gündeş E, Aday U, Çiyiltepe H, Değer K, Duman M (March 1, 2016) Intestinal Perforation after Bevacizumab Treatment in Metastatic Colon Cancer: A Rare Case. Dicle Medical Journal 43 1

IEEE

[1]D. Çetin, E. Gündeş, U. Aday, H. Çiyiltepe, K. Değer, and M. Duman, “Intestinal Perforation after Bevacizumab Treatment in Metastatic Colon Cancer: A Rare Case”, Dicle Medical Journal, vol. 43, no. 1, Mar. 2016, doi: 10.5798/diclemedj.0921.2016.01.0661.

ISNAD

Çetin, Durmuş - Gündeş, Ebubekir - Aday, Ulaş - Çiyiltepe, Hüseyin - Değer, Kamuran - Duman, Mustafa. “Intestinal Perforation After Bevacizumab Treatment in Metastatic Colon Cancer: A Rare Case”. Dicle Medical Journal 43/1 (March 1, 2016). https://doi.org/10.5798/diclemedj.0921.2016.01.0661.

JAMA

1.Çetin D, Gündeş E, Aday U, Çiyiltepe H, Değer K, Duman M. Intestinal Perforation after Bevacizumab Treatment in Metastatic Colon Cancer: A Rare Case. Dicle Medical Journal. 2016;43. doi:10.5798/diclemedj.0921.2016.01.0661.

MLA

Çetin, Durmuş, et al. “Intestinal Perforation After Bevacizumab Treatment in Metastatic Colon Cancer: A Rare Case”. Dicle Medical Journal, vol. 43, no. 1, Mar. 2016, doi:10.5798/diclemedj.0921.2016.01.0661.

Vancouver

1.Durmuş Çetin, Ebubekir Gündeş, Ulaş Aday, Hüseyin Çiyiltepe, Kamuran Değer, Mustafa Duman. Intestinal Perforation after Bevacizumab Treatment in Metastatic Colon Cancer: A Rare Case. Dicle Medical Journal. 2016 Mar. 1;43(1). doi:10.5798/diclemedj.0921.2016.01.0661

Cited By

PARMAK İZİ KAYBINA NEDEN OLAN KANSER İLAÇLARINA GENEL BAKIŞ

Doğu Karadeniz Sağlık Bilimleri Dergisi

https://doi.org/10.59312/ebshealth.1376750